Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor,DP-1904

Abstract

Abnormalities of prostanoid metabolism, which may affect renal function, were studied in lupus nephritis. The subjects were 31 patients with lupus nephritis, ten with non-renal SLE, and four with renal, non-SLE collagen disease. Urinary levels of various prostanoids, thromboxane B₂(TXB₂), 11-dehydro-TXB₂, 6-keto-PGF1α,2,3-dinor-6-keto-PGF1α and PGE₂, and plasma level of 11-dehydro-TXB₂ were determined. The effects of four days' dosing of a selective thromboxane A₂ (TXA₂ ) synthetase inhibitor, DP-1904 (DP), on pros tanoid metabolism, were also studied.

Urinary excretion of TXB₂, which reflects the renal production of TXA₂, was signifi cantly increased in the patients with lupus nephritis as compared with non-renal SLE (p < 0.05). The urinary TXB₂/6-keto-PGF1α ratio was also increased in lupus nephritis as compared with non-renal SLE or healthy controls (p < 0.01), indicating a prostanoid imbal ance, which may lead to impaired renal function and subsequent pathology. The urinary TXB₂/6-keto-PGF_1α ratio in these lupus nephritis patients showed negative correlations with Ccr and positive correlations with anti-DNA antibody titer (p < 0.001).

DP was administered orally (400 mg/day, given in two divided doses) for four days to eight lupus nephritis patients. The urinary excretion of TXB₂ and urinary TXB₂/6-keto- PGF1α ratio were decreased after one to two days of treatment in all patients. An increase in creatinine clearance used as a measure of renal function was observed in four of eight patients. Furthermore, no side effects were elicited during the four days of treatment.

The conclusions reached were that the abnormal prostanoid metabolism observed in lupus nephritis could aggravate renal function through hemodynamic mediation, and that the deviated metabolism was reversible and, at least partially, corrected by a TXA₂ syn thetase inhibitor.

Keywords

lupus nephritis prostanoids thromboxane A2 prostacyclin thromboxane A2 synthetase inhibitor

Get full access to this article

View all access options for this article.

References

Kimberly RP , Gill JR , Bowden RE et al. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 1978; 89: 336-41.

Patorono C. , Ciabattoni G. , Remuzzi G. et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invst 1985; 76: 1011-18.

Yoshida T. , Kameda H. , Akizuki M. et al. Abnormal prostanoid metabolism in systemic lupus erythematosus with pulmonary hypertension. J Rheumatol 1994 ; 21: 2393-4.

Scharschmidt LA , Lianos AE , Dunn MJ Arachidonate metabolites and the control of glomerular function. Fed Proc 1983; 42: 3058-63.

Stork JE , Dunn MJ Hemodynamic roles of thromboxane A2 and prostaglandin E2 in glomerulonephritis. J Pharmacol Exp Ther 1985; 233: 672-8.

Austin III HA , Muenz LR , Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983: 382-91.

Kasai Y. Assay Methods of Renal PG and TX and Problems, 'Prostaglandin, Kidney and Hard Tissues'. Tokyo: Tokyo Kagaku Dojin, 1988: 53.

Catella F. , Healy D. , Lawson JA et al. 11-dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 85: 5861-65.

Patrono C. , Ciabattoni G. , Filabozzi P. et al. Drugs, prostaglandin and renal function. Adv Prostaglandin Thromboxane Leukotriene Res 1985 ; 13: 131-9.

10.

Kelley VE , Ferretti A. , Izui S. et al. Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathways. J Immunol 1983; 134: 1914-9.

11.

Kelley VE , Sneve S. , Musinski S. Increased renal thromboxane production in murine lupus nephritis. J Clin Invest 1986; 77: 252-9.

12.

Patorono C. , Dunn MJ The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1-12.

13.

Pierucci A. , Simonetti BM , Pecci G. et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New Engl J Med 1989; 320: 421-5.

14.

Patrignani P. , Filabozzi P. , Catella F. et al. Differential effects of dazoxiben, a selective thromboxane synthetase inhibitor, on platelet and renal prostaglandin endoperoxide metabolism. J Pharm Exp Therapeutics 1983; 228: 472-7.

15.

Zipser RD Effects of selective inhibition of thromboxane synthesis on renal function in humans. Am J Physiol 1985; 248: F753-6.